Safety Problems With a Transdermal Patch for Migraine: Lessons From the Development, Approval, and Marketing Process-Reference-Cited by-同舟云学术

Safety Problems With a Transdermal Patch for Migraine: Lessons From the Development, Approval, and Marketing Process

Published:2018-10-27 Issue:10 Volume:58 Page:1639-1657
ISSN:0017-8748
Container-title:Headache: The Journal of Head and Face Pain
language:en
Short-container-title:Headache: The Journal of Head and Face Pain

Author:

Loder Elizabeth W.¹,Rayhill Melissa²,Burch Rebecca C.³

Affiliation:

1. Division of Headache, Department of Neurology; Brigham and Women’s Hospital, Harvard Medical School; Boston MA USA

2. Headache Division, Department of Neurology; State University of New York; Buffalo NY USA

3. Graham Headache Center, Department of Neurology, Brigham and Women’s Hospital; Harvard Medical School; Boston MA USA

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/head.13424/fullpdf

Reference51 articles.

1. Teva announces voluntary suspension of marketing for ZECUITY® in the U.S https://www.tevapharm.com/news/teva_announces_voluntary_suspension_of_marketing_for_zecuity_in_the_u_s_06_16.aspx

2. Evaluation and registration of adverse events in clinical drug trials in migraine;Tfelt-Hansen;Cephalalgia,2008

3. Drugs@FDA: FDA approved drug products https://www.accessdata.fda.gov/scripts/cder/daf/

4. OpenTrialsFDA - An OpenTrials App OpenTrials https://opentrials.net/opentrialsfda/

5. Social media listening for routine post-marketing safety surveillance;Powell;Drug Saf,2016

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The history and rationale of the development of new drugs for migraine treatment;Arquivos de Neuro-Psiquiatria;2023-12

2. Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems;Nature Reviews Drug Discovery;2023-03-27

3. Transdermal delivery systems for migraine treatment: A gap to explore;Journal of Drug Delivery Science and Technology;2022-11

4. Progress in the transdermal delivery of antimigraine drugs;Journal of Drug Delivery Science and Technology;2022-02

5. Quality by design approach to the development of transdermal patch systems and regulatory perspective;Journal of Pharmaceutical Investigation;2021-06-14